News Column

Hemispherx Biopharma Inc. Files SEC Form 8-K, Current Report (Jul. 10, 2014)

July 30, 2014

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Hemispherx Biopharma Inc. (Form 8-K) was posted on July 10, 2014.

The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).

There were 3 documents filed with this form. The SEC file number is 0000946644-14-000012.

The contact information for this company is 1617 JFK BLVD, SUITE #500, ONE PENN CENTER, PHILADELPHIA PA 19103, 215-988-0080.

Our editors provided additional information about Form 8-K: This is the "current report" that is used to report the occurrence of any material events or corporate changes which are of importance to investors or security holders and previously have not been reported by the registrant. It provides more current information on certain specified events than would Forms 10-Q or 10-K.

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see:

Keywords for this news article include: (No Diagnostic Substances), Biological Products, Biopharmaceutical Companies, Biopharmaceuticals, Biotechnology Companies, Drugs, Hemispherx Biopharma, Hemispherx Biopharma Inc., Pharmaceutical Companies, Pharmaceutical Company, SEC Filing, Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters